NCT06056310 2025-09-29
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
EMD Serono
Phase 1 Terminated
EMD Serono
Dana-Farber Cancer Institute
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
University Hospital, Ghent
University of Texas Southwestern Medical Center
Eli Lilly and Company
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)